According to a recent LinkedIn post from HistoSonics, the company plans to engage clinicians at the Society of Surgical Oncology conference in Phoenix, Ariz., from March 5–7. The post highlights an educational dinner forum focused on “Histotripsy in Practice,” featuring surgical oncology experts discussing real-world use of histotripsy technology.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also notes that HistoSonics staff will be available at booth 821 to discuss the Edison Histotripsy System, with a disclaimer that use outside liver applications remains limited to clinical investigations. For investors, this presence suggests continued physician-education efforts that may support adoption, while regulatory constraints on broader indications could remain a near‑term commercial limiter.
By targeting advanced practice providers, residents, and fellows, the activities described in the post indicate an emphasis on building long-term user familiarity and expanding the referral base for histotripsy procedures. If these outreach efforts translate into higher procedure volumes once broader indications are obtained, they could strengthen HistoSonics’ competitive position in minimally invasive oncology treatments.